The Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody. NLM AIDSLINE Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


The Vancouver Lymphadenopathy-AIDS Study: 2. Seroepidemiology of HTLV-III antibody.

Can Med Assoc J. 1985 Jun 15;132(12):1373-7. Unique Identifier : AIDSLINE MED/85227756
Jeffries E; Willoughby B; Boyko WJ; Schechter MT; Wiggs B; Fay S; O'Shaughnessy M

Abstract: Testing for antibody to human T-lymphotropic retrovirus (HTLV-III) was carried out in 448 participants in the Vancouver Lymphadenopathy-AIDS (acquired immune deficiency syndrome) Study. The overall prevalence rate of seropositivity was 34%. Of 130 seronegative subjects followed for an average of 8.5 months, 14 became seropositive; thus, the approximate annual seroconversion rate was 15%. More than 100 male sexual partners in one's lifetime, frequent receptive anal intercourse, fisting, a history of gonorrhea or hepatitis, and frequent sexual contact in clubs were found to be independent risk factors for HTLV-III seropositivity.
Keywords: Acquired Immunodeficiency Syndrome/BLOOD/COMPLICATIONS/ *EPIDEMIOLOGY/IMMUNOLOGY British Columbia Homosexuality Human HTLV-BLV Viruses/*IMMUNOLOGY Lymphatic Diseases/BLOOD/COMPLICATIONS/*EPIDEMIOLOGY/IMMUNOLOGY Male Retroviridae Infections/COMPLICATIONS Risk Sex Behavior Support, Non-U.S. Gov't JOURNAL ARTICLE

KWDacquiredimmunodeficiencysyndrome/blood/complications/KWDepidemiology/immunologybritishcolumbiahomosexualityhumanhtlv-blvviruses/KWDimmunologylymphaticdiseases/blood/complications/KWDepidemiology/immunologymaleretroviridaeinfections/complicationsrisksexbehaviorsupport,non-uKWDsKWDgov'tjournalarticle
851030
M85A0085

Copyright © 1985 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1985. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .